These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11050915)

  • 1. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
    Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
    Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
    Kuechler A; Dreidax M; Pigorsch SU; Liehr T; Claussen U; Wendt TG; Dunst J
    Strahlenther Onkol; 2003 Jul; 179(7):493-8. PubMed ID: 12835887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).
    Sauer R; Fietkau R; Wittekind C; Martus P; Rödel C; Hohenberger W; Jatzko G; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R
    Strahlenther Onkol; 2001 Apr; 177(4):173-81. PubMed ID: 11370551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].
    Rödel C; Fietkau R; Keilholz L; Grabenbauer GG; Kessler H; Martus P; Sauer R
    Strahlenther Onkol; 1997 Aug; 173(8):415-21. PubMed ID: 9289858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
    Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
    Sauer R; Fietkau R; Wittekind C; Rödel C; Martus P; Hohenberger W; Tschmelitsch J; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R;
    Colorectal Dis; 2003 Sep; 5(5):406-15. PubMed ID: 12925071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
    Myerson RJ; Valentini V; Birnbaum EH; Cellini N; Coco C; Fleshman JW; Gambacorta MA; Genovesi D; Kodner IJ; Picus J; Ratkin GA; Read TE
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1299-308. PubMed ID: 11483342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
    Trog D; Bank P; Wendt TG; Koscielny S; Beleites E
    Strahlenther Onkol; 1999 Sep; 175(9):444-9. PubMed ID: 10518978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
    Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
    Myerson R
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):86-90. PubMed ID: 11917291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
    Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
    J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility.
    Dencausse Y; Sturm J; Hartung G; Dietzler P; Edler L; Bambach M; Wojatschek C; Lindemann H; Qeisser W
    Onkologie; 2001 Oct; 24(5):476-80. PubMed ID: 11694775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: a feasibility study.
    Lupattelli M; Maranzano E; Bellavita R; Natalini G; Corgna E; Rossetti R; Trippa F; Mascioni F; Sidoni A; Anselmo P; Buzzi F; Brugia M; Latini P
    Tumori; 2005; 91(6):498-504. PubMed ID: 16457149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
    Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
    J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial.
    Athanassiou H; Antonadou D; Coliarakis N; Kouveli A; Synodinou M; Paraskevaidis M; Sarris G; Georgakopoulos GR; Panousaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1154-60. PubMed ID: 12829154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.